When was Chosa Oncology founded?

Chosa Oncology was founded in 2023.

Where is Chosa Oncology located?

Chosa Oncology is headquartered in Lund, Sweden.

How many employees does Chosa Oncology have?

As of Aug 31, 2026, the latest employee count at Chosa Oncology is 1.

Where does Chosa Oncology rank among its competitors?

Chosa Oncology ranks 1007th amongst 2449 active competitors, of which 831 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Chosa Oncology?

Chosa Oncology's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Chosa Oncology - 2026 Company Profile & Competitors

Chosa Oncology is an acquired company based in Lund (Sweden), founded in 2023. It operates as a Developer of vaccines for the treatment of metastatic cancer. The company has 2449 active competitors, including 831 funded and 613 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of vaccines for the treatment of metastatic cancer. The company's products include iCIP (LiPlaCis® and DRP® together) consists of two innovative technologies that can potentially contribute to more effective cancer care. LiPlaCis is a liposomal formulation of cisplatin enabling direct delivery of this known agent to tumor sites.

Website: www.chosaoncology.com/
Email ID: *****@chosa.bio
Phone Number: +46 **********

Key Metrics

Founded Year

2023

Location

Lund, Sweden

Stage

Acquired

Ranked

1007^th among 2449 active competitors

Employee Count

1 as on Aug 31, 2026

Similar Companies

VBI Vaccines & 29 more

Exit Details

Acquired by RhoVac (Jan 18, 2023)

View Chosa Oncology's full profile

Chosa Oncology got acquired by RhoVac on Jan 18, 2023.

Click here to take a look at Chosa Oncology's acquisition in detail

Chosa Oncology is a funded company.

Chosa Oncology's employee count trend

Chosa Oncology has 1 employees as of Aug 26. Here is Chosa Oncology's employee count trend over the years:

Uncover Chosa Oncology's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Chosa Oncology include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Chosa Oncology, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
7th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
8th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
9th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
10th	Celularity 2016, Warren (United States), Public	Developer of allogeneic cell therapies to treat multiple diseases	$290M	Celgene, Dreyfus Family Office & 8 others	71/100
1007th	Chosa Oncology 2023, Lund (Sweden), Acquired	Developer of vaccines for the treatment of metastatic cancer	-	-	36/100